Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Current Perspectives on the Role of Laser Therapy

References

• Shifren JL. Genitourinary syndrome of menopause. Clin Obstet Gynecol. 2018;61(3):508–516. doi:10.1097/GRF.0000000000000380
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063–1068. doi:10.1097/GME.0000000000000329
   PubMed Web of Science ®Google Scholar
• Simon JA, Goldstein I, Kim NN, et al. The role of androgens in the treatment of Genitourinary Syndrome of Menopause (GSM): International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause. 2018;25(7):837–847. doi:10.1097/GME.0000000000001138
   PubMed Web of Science ®Google Scholar
• Falk SJ, Bober S. Vaginal Health During Breast Cancer Treatment. Curr Oncol Rep. 2016;18(5):32. doi:10.1007/s11912-016-0517-x
   PubMed Web of Science ®Google Scholar
• Cox P, Panay N. Vulvovaginal atrophy in women after cancer. Climacteric. 2019;22(6):565–571. doi:10.1080/13697137.2019.1643180
   PubMed Web of Science ®Google Scholar
• Nappi RE, Martini E, Cucinella L, et al. Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for healthy aging in women. Front Endocrinol. 2019;10:561. doi:10.3389/fendo.2019.00561
   PubMed Web of Science ®Google Scholar
• Lester J, Pahouja G, Andersen B, Lustberg M. Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. J Pers Med. 2015;5(2):50–66. doi:10.3390/jpm5020050
   PubMed Web of Science ®Google Scholar
• Crean-Tate KK, Faubion SS, Pederson HJ, Vencill JA, Batur P. Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy. Am J Obstet Gynecol. 2020;222(2):103–113. doi:10.1016/j.ajog.2019.08.043
   PubMed Web of Science ®Google Scholar
• Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas. 2003;45(1):29–38. doi:10.1016/s03785122(03)00087-2
   PubMed Web of Science ®Google Scholar
• Santen RJ, Stuenkel CA, Davis SR, Pinkerton JV, Gompel A, Lumsden MA. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. 2017;102(10):3647–3661. doi:10.1210/jc.2017-01138
   PubMed Web of Science ®Google Scholar
• Smith KL, Verma N, Blackford AL, et al. Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation. NPJ Breast Cancer. 2022;8(1):53. doi:10.1038/s41523-022-00414-0
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Bruyniks N, Particco M, Panay N; EVES Study Investigators. The European Vulvovaginal Epidemiological Survey (EVES). Impact of history of breast cancer on prevalence, symptoms, sexual function and quality of life related to vulvovaginal atrophy. Gynecol Endocrinol. 2021;37(1):78–82. doi:10.1080/09513590.2020.1813273
   PubMed Web of Science ®Google Scholar
• Cook ED, Iglehart EI, Baum G, Schover LL, Newman LL. Missing documentation in breast cancer survivors: genitourinary syndrome of menopause. Menopause. 2017;24(12):1360–1364. doi:10.1097/GME.0000000000000926
   PubMed Web of Science ®Google Scholar
• Lindau ST, Abramsohn EM, Matthews AC. A manifesto on the preservation of sexual function in women and girls with cancer. Am J Obstet Gynecol. 2015;213(2):166–174. doi:10.1016/j.ajog.2015.03.039
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Larkin L, Krychman M, Parish SJ, Bernick B, Mirkin S. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause. 2019;26(2):124–131. doi:10.1097/GME.0000000000001194
   PubMed Web of Science ®Google Scholar
• Biglia N, Bounous VE, D’Alonzo M, et al. Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists. Clin Breast Cancer. 2017;17(8):611–617. doi:10.1016/j.clbc.2017.05.008
   PubMed Web of Science ®Google Scholar
• Biglia N, Del Pup L, Masetti R, Villa P, Nappi RE. Vulvovaginal atrophy (VVA) in breast cancer survivors (BCS) is still an unmet medical need: results of an Italian Delphi Panel. Support Care Cancer. 2020;28(6):2507–2512. doi:10.1007/s00520-019-05272-4
   PubMed Web of Science ®Google Scholar
• The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976–992. doi:10.1097/GME.0000000000001609
   PubMed Web of Science ®Google Scholar
• Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 2018;25(6):596–608. doi:10.1097/GME.0000000000001121
   PubMed Web of Science ®Google Scholar
• “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists’ Committee on Clinical Consensus—Gynecology. Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus. Obstet Gynecol. 2021;138(6):950–960. doi:10.1097/AOG.0000000000004601
   PubMed Web of Science ®Google Scholar
• Carter J, Lacchetti C, Andersen BL, et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology clinical practice guideline adaptation of Cancer Care Ontario guideline. J Clin Oncol. 2018;36(5):492–511. doi:10.1200/JCO.2017.75.8995
   PubMed Web of Science ®Google Scholar
• Hillard TC, Nappi RE. The heat is on. Climacteric. 2020;23(sup1):S1–S2. doi:10.1080/13697137.2020.1828855
   PubMed Web of Science ®Google Scholar
• Biglia N, Bounous VE, Sgro LG, D’Alonzo M, Pecchio S, Nappi RE. Genitourinary syndrome of menopause in breast cancer survivors: are we facing new and safe hopes? Clin Breast Cancer. 2015;15(6):413–420. doi:10.1016/j.clbc.2015.06.005
   PubMed Web of Science ®Google Scholar
• Zerbinati N, Serati M, Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci. 2015;30(1):429–436. doi:10.1007/s10103-014-1677-2
   PubMed Web of Science ®Google Scholar
• Hillard TC. Lasers in the era of evidence-based medicine. Climacteric. 2020;23(sup1):S6–S10. doi:10.1080/13697137.2020.1774536
   PubMed Web of Science ®Google Scholar
• Adelman M, Nygaard IE. Time for a “Pause” on the use of vaginal laser. JAMA. 2021;326(14):1378–1380. doi:10.1001/jama.2021.14809
   PubMed Web of Science ®Google Scholar
• Nappi RE, Murina F, Perrone G, Villa P, Biglia N. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy. Minerva Ginecol. 2017;69(4):370–380. doi:10.23736/S0026-4784.17.04064-3
   PubMedGoogle Scholar
• Shobeiri SA, Kerkhof MH, Minassian VA, Bazi T; IUGA Research and Development Committee. IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity. Int Urogynecol J. 2019;30(3):371–376. doi:10.1007/s00192-018-3830-0
   PubMed Web of Science ®Google Scholar
• Phillips C, Hillard T, Salvatore S, Cardozo L, Toozs-Hobson P; Royal College of Obstetricians and Gynaecologists. Laser treatment for genitourinary syndrome of menopause: scientific impact Paper No. 72 (July 2022). BJOG. 2022;129(12):e89–e94. doi:10.1111/1471-0528.17195
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [homepage on the Internet]. FDA warns against use of energy-based devices to perform vaginal “rejuvenation” or vaginal cosmetic procedures: FDA safety communication. Available from: https://www.fda.gov/medical-devices/safety-communications/fdawarns-against-use-energy-based-devices-perform-vaginal-rejuvenation-or-vaginal-cosmetic. Accessed November 19, 2022.
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Pagano T, De Rosa P, Vallone R, et al. Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study. Menopause. 2016;23(10):1108–1113. doi:10.1097/GME.0000000000000672
   PubMed Web of Science ®Google Scholar
• Pieralli A, Fallani MG, Becorpi A, et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet. 2016;294(4):841–846. doi:10.1007/s00404-016-4118-6
   PubMed Web of Science ®Google Scholar
• Pagano T, De Rosa P, Vallone R, et al. Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. Menopause. 2018;25(6):657–662. doi:10.1097/GME.0000000000001053
   PubMed Web of Science ®Google Scholar
• Becorpi A, Campisciano G, Zanotta N, et al. Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects. Lasers Med Sci. 2018;33(5):1047–1054. doi:10.1007/s10103-018-2471-3
   PubMed Web of Science ®Google Scholar
• Pearson A, Booker A, Tio M, Marx G. Vaginal CO2 laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study. Breast Cancer Res Treat. 2019;178(1):135–140. doi:10.1007/s10549-019-05384-9
   PubMed Web of Science ®Google Scholar
• Gittens P, Mullen G. The effects of fractional microablative CO2 laser therapy on sexual function in postmenopausal women and women with a history of breast cancer treated with endocrine therapy. J Cosmet Laser Ther. 2019;21(3):127–131. doi:10.1080/14764172.2018.1481510
   PubMed Web of Science ®Google Scholar
• Angioli R, Stefano S, Filippini M, et al. Effectiveness of CO2 laser on urogenital syndrome in women with a previous gynecological neoplasia: a multicentric study. Int J Gynecol Cancer. 2020;30(5):590–595. doi:10.1136/ijgc-2019-001028
   PubMed Web of Science ®Google Scholar
• Hersant B, Werkoff G, Sawan D, et al. Carbon dioxide laser treatment for vulvovaginal atrophy in women treated for breast cancer: preliminary results of the feasibility EPIONE trial. Ann Chir Plast Esthet. 2020;65(4):e23–e31. doi:10.1016/j.anplas.2020.05.002
   PubMed Web of Science ®Google Scholar
• Quick AM, Zvinovski F, Hudson C, et al. Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors. Support Care Cancer. 2020;28(8):3669–3677. doi:10.1007/s00520-019-05211-3
   PubMed Web of Science ®Google Scholar
• Veron L, Wehrer D, Annerose-Zéphir G, et al. Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up. Breast Cancer Res Treat. 2021;188(2):501–509. doi:10.1007/s10549-021-06226-3
   PubMed Web of Science ®Google Scholar
• Siliquini GP, Bounous VE, Novara L, Giorgi M, Bert F, Biglia N. Fractional CO₂ vaginal laser for the genitourinary syndrome of menopause in breast cancer survivors. Breast J. 2021;27(5):448–455. doi:10.1111/tbj.14211
   PubMed Web of Science ®Google Scholar
• Salvatore S, Nappi RE, Casiraghi A, et al. Microablative fractional CO2 laser for vulvovaginal atrophy in women with a history of breast cancer: a pilot study at 4-week follow-up. Clin Breast Cancer. 2021;21(5):e539–e546. doi:10.1016/j.clbc.2021.01.006
   PubMed Web of Science ®Google Scholar
• Quick AM, Zvinovski F, Hudson C, et al. Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy. Menopause. 2021;28(6):642–649. doi:10.1097/GME.0000000000001738
   PubMed Web of Science ®Google Scholar
• Gardner AN, Aschkenazi SO. The short-term efficacy and safety of fractional CO2 laser therapy for vulvovaginal symptoms in menopause, breast cancer, and lichen sclerosus. Menopause. 2021;28(5):511–516. doi:10.1097/GME.0000000000001727
   PubMed Web of Science ®Google Scholar
• Quick AM, Hundley A, Evans C, et al. Long-term follow-up of fractional CO2 laser therapy for genitourinary syndrome of menopause in breast cancer survivors. J Clin Med. 2022;11(3):774. doi:10.3390/jcm11030774
   PubMed Web of Science ®Google Scholar
• Mension E, Alonso I, Anglès-Acedo S, et al. Effect of fractional carbon dioxide vs sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause: the LIGHT randomized clinical trial. JAMA Netw Open. 2023;6(2):e2255697. doi:10.1001/jamanetworkopen.2022.55697
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Levancini M. Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. Menopause. 2017;24(3):316–319. doi:10.1097/GME.0000000000000761
   PubMed Web of Science ®Google Scholar
• Mothes AR, Runnebaum M, Runnebaum IB. Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment. J Cancer Res Clin Oncol. 2018;144(5):955–960. doi:10.1007/s00432-018-2614-8
   PubMed Web of Science ®Google Scholar
• Arêas F, Valadares ALR, Conde DM, Costa-Paiva L. The effect of vaginal erbium laser treatment on sexual function and vaginal health in women with a history of breast cancer and symptoms of the genitourinary syndrome of menopause: a prospective study. Menopause. 2019;26(9):1052–1058. doi:10.1097/GME.0000000000001353
   PubMed Web of Science ®Google Scholar
• Gold D, Nicolay L, Avian A, et al. Vaginal laser therapy versus hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: a randomized controlled trial. Maturitas. 2022;167:1–7. doi:10.1016/j.maturitas.2022.08.013
   PubMed Web of Science ®Google Scholar
• Gordon C, Gonzales S, Krychman ML. Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy. Menopause. 2019;26(4):423–427. doi:10.1097/GME.0000000000001293
   PubMed Web of Science ®Google Scholar
• Knight C, Logan V, Fenlon D. A systematic review of laser therapy for vulvovaginal atrophy/genitourinary syndrome of menopause in breast cancer survivors. Ecancermedicalscience. 2019;13:988. doi:10.3332/ecancer.2019.988
   PubMed Web of Science ®Google Scholar
• Jha S, Wyld L, Krishnaswamy PH. The impact of vaginal laser treatment for genitourinary syndrome of menopause in breast cancer survivors: a systematic review and meta-analysis. Clin Breast Cancer. 2019;19(4):e556–e562. doi:10.1016/j.clbc.2019.04.007
   PubMed Web of Science ®Google Scholar
• D’Oria O, Giannini A, Buzzaccarini G, et al. Fractional Co2 laser for vulvo-vaginal atrophy in gynecologic cancer patients: a valid therapeutic choice? A systematic review. Eur J Obstet Gynecol Reprod Biol. 2022;277:84–89. doi:10.1016/j.ejogrb.2022.08.012
   PubMed Web of Science ®Google Scholar
• Jugulytė N, Žukienė G, Bartkevičienė D. Emerging use of vaginal laser to treat genitourinary syndrome of menopause for breast cancer survivors: a review. Medicina. 2023;59:132. doi:10.3390/medicina59010132
   PubMedGoogle Scholar
• Athanasiou S, Pitsouni E, Douskos A, Salvatore S, Loutradis D, Grigoriadis T. Intravaginal energy-based devices and sexual health of female cancer survivors: a systematic review and meta-analysis. Lasers Med Sci. 2020;35(1):1–11. doi:10.1007/s10103-019-02855-9
   PubMed Web of Science ®Google Scholar
• Filippini M, Porcari I, Ruffolo AF, et al. CO2-laser therapy and genitourinary syndrome of menopause: a systematic review and meta-analysis. J Sex Med. 2022;19(3):452–470. doi:10.1016/j.jsxm.2021.12.010
   PubMed Web of Science ®Google Scholar
• Liu M, Li F, Zhou Y, Cao Y, Li S, Li Q. Efficacy of CO2 laser treatment in postmenopausal women with vulvovaginal atrophy: a meta-analysis. Int J Gynaecol Obstet. 2022;158(2):241–251. doi:10.1002/ijgo.13973
   PubMed Web of Science ®Google Scholar
• Mension E, Alonso I, Tortajada M, et al. Vaginal laser therapy for genitourinary syndrome of menopause - systematic review. Maturitas. 2022;156:37–59. doi:10.1016/j.maturitas.2021.06.005
   PubMed Web of Science ®Google Scholar
• Khamis Y, Abdelhakim AM, Labib K, et al. Vaginal CO2 laser therapy versus sham for genitourinary syndrome of menopause management: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2021;28(11):1316–1322. doi:10.1097/GME.0000000000001845
   PubMed Web of Science ®Google Scholar
• Quick AM, Dockter T, Le-Rademacher J, et al. Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. Maturitas. 2021;144:37–44. doi:10.1016/j.maturitas.2020.10.018
   PubMed Web of Science ®Google Scholar
• Cruff J, Khandwala S. A double-blind randomized sham-controlled trial to evaluate the efficacy of fractional carbon dioxide laser therapy on genitourinary syndrome of menopause. J Sex Med. 2021;18(4):761–769. doi:10.1016/j.jsxm.2021.01.188
   PubMed Web of Science ®Google Scholar
• Li FG, Maheux-Lacroix S, Deans R, et al. Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms: a randomized clinical trial. JAMA. 2021;326(14):1381–1389. doi:10.1001/jama.2021.14892
   PubMed Web of Science ®Google Scholar
• Page AS, Verbakel JY, Verhaeghe J, Latul YP, Housmans S, Deprest J. Laser versus sham for genitourinary syndrome of menopause: a randomised controlled trial. BJOG. 2022. doi:10.1111/1471-0528.17335
   Google Scholar
• Mortensen OE, Christensen SE, Løkkegaard E. The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: a state-of-The-art review. Acta Obstet Gynecol Scand. 2022;101(6):657–692. doi:10.1111/aogs.14353
   PubMed Web of Science ®Google Scholar
• Pérez-López FR, Varikasuvu SR. Vulvovaginal atrophy management with a laser: the placebo effect or the conditioning Pavlov reflex. Climacteric. 2022;25(4):323–326. doi:10.1080/13697137.2022.2050207
   PubMed Web of Science ®Google Scholar
• Mackova K, Mazzer AM, Mori Da Cunha M, et al. Vaginal Er:YAG laser application in the menopausal ewe model: a randomised estrogen and sham-controlled trial. BJOG. 2021;128(6):1087–1096. doi:10.1111/1471-0528.16558
   PubMedGoogle Scholar
• Tadir Y, Gaspar A, Lev-Sagie A, et al. Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med. 2017;49(2):137–159. doi:10.1002/lsm.22637
   PubMed Web of Science ®Google Scholar
• Dutra PFSP, Heinke T, Pinho SC, et al. Comparison of topical fractional CO2 laser and vaginal estrogen for the treatment of genitourinary syndrome in postmenopausal women: a randomized controlled trial. Menopause. 2021;28(7):756–763. doi:10.1097/GME.0000000000001797
   PubMed Web of Science ®Google Scholar
• Gaspar A, Silva J, Calderon A, Di Placido V, Vizintin Z. Histological findings after non-ablative Er:YAG laser therapy in women with severe vaginal atrophy. Climacteric. 2020;23(sup1):S11–S13. doi:10.1080/13697137.2020.1764525
   PubMed Web of Science ®Google Scholar
• Perino A, Calligaro A, Forlani F, et al. Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser. Maturitas. 2015;80(3):296–301. doi:10.1016/j.maturitas.2014.12.006
   PubMed Web of Science ®Google Scholar
• Lang P, Dell JR, Rosen L, Weiss P, Karram M. Fractional CO2 laser of the vagina for genitourinary syndrome of menopause: is the out-of-pocket cost worth the outcome of treatment? Lasers Surg Med. 2017;49(10):882–885. doi:10.1002/lsm.22713
   PubMed Web of Science ®Google Scholar
• Di Donato V, O D, Scudo M, et al. Safety evaluation of fractional CO2 laser treatment in post-menopausal women with vaginal atrophy: a prospective observational study. Maturitas. 2020;135:34–39. doi:10.1016/j.maturitas.2020.02.009
   PubMed Web of Science ®Google Scholar
• Preti M, Vieira-Baptista P, Digesu GA, et al. The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: an ICS/ISSVD best practice consensus document. Neurourol Urodyn. 2019;38(3):1009–1023. doi:10.1002/nau.23931
   PubMed Web of Science ®Google Scholar
• Cucinella L, Martini E, Tiranini L, et al. Genitourinary syndrome of menopause: should we treat symptoms or signs? Curr Opin Endocr Metab Res. 2022;22:100386. doi:10.1016/j.coemr.2022.100386
   Google Scholar
• Castelo-Branco C, Mension E. Are we assessing genitourinary syndrome of menopause properly? Climacteric. 2021;24(6):529–530. doi:10.1080/13697137.2021.1945573
   PubMed Web of Science ®Google Scholar
• Phillips NA, Bachmann GA. The genitourinary syndrome of menopause. Menopause. 2021;28(5):579–588. doi:10.1097/GME.0000000000001728
   PubMed Web of Science ®Google Scholar
• Balica AC, Cooper AM, McKevitt MK, et al. Dyspareunia Related to GSM: association of Total Vaginal Thickness via Transabdominal Ultrasound. J Sex Med. 2019;16(12):2038–2042. doi:10.1016/j.jsxm.2019.08.019
   PubMed Web of Science ®Google Scholar
• Peker H, Gursoy A. Relationship between genitourinary syndrome of menopause and 3D high-frequency endovaginal ultrasound measurement of vaginal wall thickness. J Sex Med. 2021;18(7):1230–1235. doi:10.1016/j.jsxm.2021.05.004
   PubMed Web of Science ®Google Scholar
• Athanasiou S, Pitsouni E, Antonopoulou S, et al. The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women. Climacteric. 2016;19(5):512–518. doi:10.1080/13697137.2016.1212006
   PubMed Web of Science ®Google Scholar
• Sipos AG, Pákozdy K, Jäger S, Larson K, Takacs P, Kozma B. Fractional CO2 laser treatment effect on cervicovaginal lavage zinc and copper levels: a prospective cohort study. BMC Womens Health. 2021;21(1):235. doi:10.1186/s12905-021-01379-1
   PubMed Web of Science ®Google Scholar
• Lensen S, Bell RJ, Carpenter JS, et al. A core outcome set for genitourinary symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative. Menopause. 2021;28(8):859–866. doi:10.1097/GME.0000000000001788
   PubMed Web of Science ®Google Scholar
• Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N; EVES Study Investigators. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286–291. doi:10.1080/13697137.2018.1446930
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Bruyniks N, Particco M, Panay N; EVES Study investigators. The burden of vulvovaginal atrophy on women’s daily living: implications on quality of life from a face-to-face real-life survey. Menopause. 2019;26(5):485–491. doi:10.1097/GME.0000000000001260
   PubMed Web of Science ®Google Scholar
• Particco M, Djumaeva S, Nappi RE, Panay N, Palacios S; EVES Study investigators. The European Vulvovaginal Epidemiological Survey (EVES): impact on sexual function of vulvovaginal atrophy of menopause. Menopause. 2020;27(4):423–429. doi:10.1097/GME.0000000000001496
   PubMed Web of Science ®Google Scholar
• Panay N, Palacios S, Bruyniks N, Particco M, Nappi RE; EVES Study investigators. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas. 2019;124:55–61. doi:10.1016/j.maturitas.2019.03.013
   PubMed Web of Science ®Google Scholar
• Flynn KE, Lin L, Carter J, et al. Correspondence between clinician ratings of vulvovaginal health and patient-reported sexual function after cancer. J Sex Med. 2021;18(10):1768–1774. doi:10.1016/j.jsxm.2021.07.011
   PubMed Web of Science ®Google Scholar
• Kieseker GA, Anderson DJ, Porter-Steele J, McCarthy AL. A psychometric evaluation of the Female Sexual Function Index in women treated for breast cancer. Cancer Med. 2022;11(6):1511–1523. doi:10.1002/cam4.4516
   PubMed Web of Science ®Google Scholar
• Nappi RE. New attitudes to sexuality in the menopause: clinical evaluation and diagnosis. Climacteric. 2007;10(Suppl 2):105–108. doi:10.1080/13697130701599876
   PubMedGoogle Scholar
• Mension E, Alonso I, Castelo-Branco C. Genitourinary syndrome of menopause: current treatment options in breast cancer survivors - systematic review. Maturitas. 2021;143:47–58. doi:10.1016/j.maturitas.2020.08.010
   PubMed Web of Science ®Google Scholar
• Vegunta S, Kuhle CL, Vencill JA, Lucas PH, Mussallem DM. Sexual health after a breast cancer diagnosis: addressing a forgotten aspect of survivorship. J Clin Med. 2022;11(22):6723. doi:10.3390/jcm11226723
   PubMed Web of Science ®Google Scholar
• Tounkel I, Nalubola S, Schulz A, Lakhi N. Sexual health screening for gynecologic and breast cancer survivors: a review and critical analysis of validated screening tools. Sex Med. 2022;10(2):100498. doi:10.1016/j.esxm.2022.100498
   PubMed Web of Science ®Google Scholar
• Mlakar I, Lin S, Nateqi J, et al. Establishing an expert consensus on key indicators of the quality of life among breast cancer survivors: a modified delphi study. J Clin Med. 2022;11(7):2041. doi:10.3390/jcm11072041
   PubMed Web of Science ®Google Scholar
• Hickey M, Emery LI, Gregson J, Doherty DA, Saunders CM. The multidisciplinary management of menopausal symptoms after breast cancer: a unique model of care. Menopause. 2010;17(4):727–733. doi:10.1097/gme.0b013e3181d672f6
   PubMed Web of Science ®Google Scholar
• Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: an update. World J Clin Oncol. 2022;13(2):71–100. doi:10.5306/wjco.v13.i2.71
   PubMed Web of Science ®Google Scholar
• Faubion SS, Kingsberg SA. Understanding the unmet sexual health needs of women with breast cancer. Menopause. 2019;26(8):811–813. doi:10.1097/GME.0000000000001372
   PubMed Web of Science ®Google Scholar
• Vizza R, Capomolla EM, Tosetto L, et al. Sexual dysfunctions in breast cancer patients: evidence in context. Sex Med Rev. 2023:qead006. doi:10.1093/sxmrev/qead006
   Web of Science ®Google Scholar
• Nappi RE, Martella S, Albani F, Cassani C, Martini E, Landoni F. Hyaluronic acid: a valid therapeutic option for early management of genitourinary syndrome of menopause in cancer survivors? Healthcare. 2022;10(8):1528. doi:10.3390/healthcare10081528
   Web of Science ®Google Scholar
• Garzon S, Apostolopoulos V, Stojanovska L, Ferrari F, Mathyk BA, Laganà AS. Non-oestrogenic modalities to reverse urogenital aging. Prz Menopauzalny. 2021;20(3):140–147. doi:10.5114/pm.2021.109772
   PubMedGoogle Scholar
• Jang YC, Leung CY, Huang HL. Comparison of severity of genitourinary syndrome of menopause symptoms after carbon dioxide laser vs vaginal estrogen therapy: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(9):e2232563. doi:10.1001/jamanetworkopen.2022.32563
   PubMed Web of Science ®Google Scholar
• Mension E, Alonso I, Cebrecos I, et al. Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study. Climacteric. 2022;25(5):476–482. doi:10.1080/13697137.2022.2050208
   PubMed Web of Science ®Google Scholar
• Cai B, Simon J, Villa P, et al. No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA). Maturitas. 2020;142:38–44. doi:10.1016/j.maturitas.2020.06.021
   PubMed Web of Science ®Google Scholar
• Nappi RE, Cucinella L, Martini E, Cassani C. The role of hormone therapy in urogenital health after menopause. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101595. doi:10.1016/j.beem.2021.101595
   PubMed Web of Science ®Google Scholar
• Salvatore S, Benini V, Ruffolo AF, et al. Current challenges in the pharmacological management of genitourinary syndrome of menopause. Expert Opin Pharmacother. 2022. doi:10.1080/14656566.2022.2152326
   Web of Science ®Google Scholar
• Simon JA, Davis SR, Althof SE, et al. Sexual well-being after menopause: an International Menopause Society White Paper. Climacteric. 2018;21(5):415–427. doi:10.1080/13697137.2018.1482647
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Mili N, Paschou SA, Armeni A, Georgopoulos N, Goulis DG, Lambrinoudaki I. Genitourinary syndrome of menopause: a systematic review on prevalence and treatment. Menopause. 2021;28(6):706–716. doi:10.1097/GME.0000000000001752
   PubMed Web of Science ®Google Scholar
• Tranoulis A, Georgiou D, Michala L. Laser treatment for the management of genitourinary syndrome of menopause after breast cancer. Hope or hype? Int Urogynecol J. 2019;30(11):1879–1886. doi:10.1007/s00192-019-04051-3
   PubMed Web of Science ®Google Scholar